Cryoport Q1 revenue $41M, up 10% YoY; cell & gene therapy revenue up 33%

Cryoport, Inc.

2025-Q1 EPS reported -$0.28 revenue$41,040,000

Commercial Cell & Gene therapy revenue $7.2M, up 33% YoY; supported 19 commercial therapies.
Life Sciences Services revenue $22.9M (+17%); Products $18.2M (+2%); total continuing ops $41.0M.
Strategic DHL partnership; CRYOPDP divestiture expected Q2/Q3 2025, providing capital infusion.
Supported 711 global clinical trials (net +36 YoY); 79 Phase 3; six BLA/MAA filings in Q1.
Abeona's ZEVASKYN FDA-approved post-Q1; 17 more application filings anticipated in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.